Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations

por Yang, Zhengyu, Chen, Ya, Wang, Yanan, Wang, Shuyuan, Hu, Minjuan, Zhang, Bo, Han, Baohui
Publicado 2021

PlGF knockdown attenuates hypoxia-induced stimulation of cell proliferation and glycolysis of lung adenocarcinoma through inhibiting Wnt/β-catenin pathway

por Zhang, Wei, Zhang, Yanwei, Zhou, Wensheng, Qian, Fangfei, Hu, Minjuan, Chen, Ya, Lu, Jun, Lou, Yuqing, Han, Baohui
Publicado 2021

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC

por Chen, Ya, Yang, Zhengyu, Wang, Yanan, Hu, Minjuan, Zhang, Bo, Zhang, Yanwei, Qian, Fangfei, Zhang, Wei, Han, Baohui
Publicado 2021

Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study

por Chen, Ya, Wang, Yanan, Yang, Zhengyu, Hu, Minjuan, Zhang, Yanwei, Qian, Fangfei, Zhang, Wei, Zhang, Bo, Han, Baohui
Publicado 2021

Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (≥75 Years Old) With Non-Small-Cell Lung Cancer

por Yang, Zhengyu, Chen, Ya, Wang, Yanan, Hu, Minjuan, Qian, Fangfei, Zhang, Yanwei, Zhang, Bo, Zhang, Wei, Han, Baohui
Publicado 2022

Case report: Spontaneous remission in lung carcinoma with a late relapse after adjuvant immunotherapy: Exceptional tumor micro-environment

por Chen, Yan, Guan, Wenhui, Zhong, Changhao, Deng, Jiaxi, Hu, Minjuan, Mo, Wenwei, Xie, Xiaohong, Li, Shiyue, Zhou, Chengzhi, Lin, Xinqing
Publicado 2023

Serum TNFRII: A promising biomarker for predicting the risk of subcentimetre lung adenocarcinoma

por Hu, Minjuan, Zhang, Yanwei, Sun, Beibei, Lou, Yuqing, Zhang, Xueyan, Wang, Huimin, Huang, Chengya, Zhang, Wei, Chu, Tianqing, Han, Baohui
Publicado 2020

CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients

por Zhang, Yanwei, Sun, Beibei, Hu, Minjuan, Lou, Yuqing, Lu, Jun, Zhang, Xueyan, Wang, Huimin, Qian, Jialin, Chu, Tianqing, Han, Baohui
Publicado 2020

Comparative Study of Pulmonary Combined Large-Cell Neuroendocrine Carcinoma and Combined Small-Cell Carcinoma in Surgically Resected High-Grade Neuroendocrine Tumors of the Lung

por Wang, Yanan, Qian, Fangfei, Chen, Ya, Yang, Zhengyu, Hu, Minjuan, Lu, Jun, Zhang, Yanwei, Zhang, Wei, Cheng, Lei, Han, Baohui
Publicado 2021

Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells

por Lu, Jun, Xu, Wei, Qian, Jie, Wang, Shuyuan, Zhang, Bo, Zhang, Lele, Qiao, Rong, Hu, Minjuan, Zhao, Yiming, Zhao, Xiaodong, Han, Baohui
Publicado 2019

TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer

por Lu, Jun, Zhong, Runbo, Lou, Yuqing, Hu, Minjuan, Yang, Zhengyu, Wang, Yanan, Chen, Ya, Zou, Benkun, Zhang, Wei, Wang, Huimin, Han, Baohui
Publicado 2021

Correction: Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells

por Lu, Jun, Xu, Wei, Qian, Jie, Wang, Shuyuan, Zhang, Bo, Zhang, Lele, Qiao, Rong, Hu, Minjuan, Zhao, Yiming, Zhao, Xiaodong, Han, Baohui
Publicado 2022

ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients

por Lu, Jun, Zhang, Yanwei, Lou, Yuqing, Yan, Bo, Zou, Benkun, Hu, Minjuan, Wang, Yanan, Chen, Ya, Yang, Zhengyu, Wang, Huimin, Zhang, Wei, Han, Baohui
Publicado 2021

Local consolidative therapy for synchronous oligometastatic non‐small cell lung cancer treated with first‐line pembrolizumab: A retrospective observational study

por Chen, Ya, Wang, Yanan, Yang, Zhengyu, Hu, Minjuan, Lu, Jun, Zhang, Yanwei, Qian, Fangfei, Zhang, Bo, Wang, Shuyuan, Wang, Kai, Zhang, Wei, Han, Baohui
Publicado 2022

Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update

por Lu, Jun, Chu, Tianqing, Liu, Hongyu, Hu, Minjuan, Lou, Yuqing, Zhang, Yanwei, Gao, Zhiqiang, Zhang, Wei, Zhang, Xueyan, Wang, Huimin, Zhong, Hua, Han, Baohui
Publicado 2022

The clinicopathological and molecular characteristics of resected EGFR‐mutant lung adenocarcinoma

por Zhou, Wensheng, Liu, Zhichao, Wang, Yanan, Zhang, Yanwei, Qian, Fangfei, Lu, Jun, Wang, Huimin, Gu, Ping, Hu, Minjuan, Chen, Ya, Yang, Zhengyu, Zhao, Ruiying, Lou, Yuqing, Han, Baohui, Zhang, Wei
Publicado 2022